scholarly journals Positive Predictive Values of International Classification of Diseases, 10th Revision Coding Algorithms to Identify Patients With Autosomal Dominant Polycystic Kidney Disease

2016 ◽  
Vol 3 ◽  
pp. 205435811667913 ◽  
Author(s):  
Vinusha Kalatharan ◽  
York Pei ◽  
Kristin K. Clemens ◽  
Rebecca K. McTavish ◽  
Stephanie N. Dixon ◽  
...  
Kidney360 ◽  
2021 ◽  
pp. 10.34067/KID.0000852021
Author(s):  
Mohamad A. Kalot ◽  
Abdallah El Alayli ◽  
Mohammed Al Khatib ◽  
Nedaa Husainat ◽  
Kerri McGreal ◽  
...  

Background: A computable phenotype is an algorithm used to identify a group of patients within an electronic medical record system. Developing a computable phenotype that can accurately identify Autosomal Dominant Polycystic kidney disease (ADPKD) patients will assist researchers in defining patients eligible to participate clinical trials and other studies. Our objective was to assess the accuracy of a computable phenotype using ICD (International Classification of Diseases) 9 and 10 codes (ICD-9/10) to identify patients with ADPKD. Methods: We reviewed four random samples of approximately 250 patients based on ICD-9/10 codes from the EHR from the Kansas University Medical Center database: patients followed in nephrology clinics who had ICD-9/10 codes for ADPKD (Neph+), patients seen in nephrology clinics without ICD codes of ADPKD (Neph-), patients who were not followed in nephrology clinics with ICD codes for ADPKD (No Neph+), and patients not seen in nephrology clinics without ICD codes for ADPKD (No Neph-). We reviewed charts and determined ADPKD status based on internationally accepted diagnostic criteria for ADPKD. Results: The computable phenotype to identify patients with ADPKD who attended nephrology clinics has a sensitivity of 98.7% (95% confidence interval (95% CI); 96.4-99.7), and a specificity of 84.1% (95% CI; 79.5-88.1). For those who did not attend nephrology clinics the sensitivity was 97.1% (95% CI; 93.3-99.0), and a specificity was 82.0% (95% CI; 77.4-86.1). Conclusion: A computable phenotype using the ICD-9/10 codes can correctly identify most patients with ADPKD and can be utilized by researchers to screen healthcare records for ADPKD patient cohorts with acceptable accuracy.


2020 ◽  
Author(s):  
Vinusha Kalatharan ◽  
Eric McArthur ◽  
Danielle M Nash ◽  
Blayne Welk ◽  
Sisira Sarma ◽  
...  

Abstract Background The ability to identify patients with autosomal dominant polycystic kidney disease (ADPKD) and distinguish them from patients with similar conditions in healthcare administrative databases is uncertain. We aimed to measure the sensitivity and specificity of different ADPKD administrative coding algorithms in a clinic population with non-ADPKD and ADPKD kidney cystic disease. Methods We used a dataset of all patients who attended a hereditary kidney disease clinic in Toronto, Ontario, Canada between 1 January 2010 and 23 December 2014. This dataset included patients who met our reference standard definition of ADPKD or other cystic kidney disease. We linked this dataset to healthcare databases in Ontario. We developed eight algorithms to identify ADPKD using the International Classification of Diseases, 10th Revision (ICD-10) codes and provincial diagnostic billing codes. A patient was considered algorithm positive if any one of the codes in the algorithm appeared at least once between 1 April 2002 and 31 March 2015. Results The ICD-10 coding algorithm had a sensitivity of 33.7% [95% confidence interval (CI) 30.0–37.7] and a specificity of 86.2% (95% CI 75.7–92.5) for the identification of ADPKD. The provincial diagnostic billing code had a sensitivity of 91.1% (95% CI 88.5–93.1) and a specificity of 10.8% (95% CI 5.3–20.6). Conclusions ICD-10 coding may be useful to identify patients with a high chance of having ADPKD but fail to identify many patients with ADPKD. Provincial diagnosis billing codes identified most patients with ADPKD and also with other types of cystic kidney disease.


2020 ◽  
Vol 31 (7) ◽  
pp. 1640-1651
Author(s):  
Kyongtae T. Bae ◽  
Tiange Shi ◽  
Cheng Tao ◽  
Alan S. L. Yu ◽  
Vicente E. Torres ◽  
...  

BackgroundThe Mayo Clinic imaging classification of autosomal dominant polycystic kidney disease (ADPKD) uses height-adjusted total kidney volume (htTKV) and age to identify patients at highest risk for disease progression. However, this classification applies only to patients with typical diffuse cystic disease (class 1). Because htTKV poorly predicts eGFR decline for the 5%–10% of patients with atypical morphology (class 2), imaging-based risk modeling remains unresolved.MethodsOf 558 adults with ADPKD in the HALT-A study, we identified 25 patients of class 2A with prominent exophytic cysts (class 2Ae) and 43 patients of class 1 with prominent exophytic cysts; we recalculated their htTKVs to exclude exophytic cysts. Using original and recalculated htTKVs in association with imaging classification in logistic and mixed linear models, we compared predictions for developing CKD stage 3 and for eGFR trajectory.ResultsUsing recalculated htTKVs increased specificity for developing CKD stage 3 in all participants from 82.6% to 84.2% after adjustment for baseline age, eGFR, BMI, sex, and race. The predicted proportion of class 2Ae patients developing CKD stage 3 using a cutoff of 0.5 for predicting case status was better calibrated to the observed value of 13.0% with recalculated htTKVs (45.5%) versus original htTKVs (63.6%). Using recalculated htTKVs reduced the mean paired difference between predicted and observed eGFR from 17.6 (using original htTKVs) to 4.0 ml/min per 1.73 m2 for class 2Ae, and from −1.7 (using original htTKVs) to 0.1 ml/min per 1.73 m2 for class 1.ConclusionsUse of a recalculated htTKV measure that excludes prominent exophytic cysts facilitates inclusion of class 2 patients and reclassification of class 1 patients in the Mayo classification model.


Sign in / Sign up

Export Citation Format

Share Document